Evidence-Based Practices for Medicaid Beneficiaries with Schizophrenia and Bipolar Disorder. A. Medication Treatment and Monitoring


We examined whether beneficiaries had at least one claim for an evidence-based medication in 2007, which included any antipsychotic for schizophrenia and any antipsychotic, lithium, or certain evidence-based anticonvulsants (valproate, carbamazepine, or lamotrigine) for bipolar disorder. We also examined whether beneficiaries received these evidence-based medications for 80 percent of the days in which they were enrolled in Medicaid following the receipt of the first medication. Finally, because laboratory monitoring of certain medications is necessary to ensure that beneficiaries receive a therapeutic dose and avoid harmful side effects, we examined the extent to which beneficiaries with bipolar disorder who filled a prescription for lithium, valproate, or carbamazepine received regular monitoring of medication levels, as well as the extent to which beneficiaries who filled a prescription for an antipsychotic received screening for cardiovascular disease (cholesterol levels) and diabetes (glucose levels).

View full report


"ebpsbd.pdf" (pdf, 1005.36Kb)

Note: Documents in PDF format require the Adobe Acrobat Reader®. If you experience problems with PDF documents, please download the latest version of the Reader®